ProfoundBio to Participate in the Wells Fargo 2023 Virtual Private Biotech Symposium and Piper Sandler 35th Annual Healthcare Conference
Source:
|
Author:ProfoundBio
|
Published :2023-10-24
|
756 Views
|
Share:
ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple antibody-drug conjugate (ADC) drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages. The company's lead clinical stage programs are rinatabart sesutecan (PRO1184), an ADC targeting folate receptor alpha, and PRO1160, an ADC targeting CD70. ProfoundBio is headquartered in Seattle, WA, USA with R&D operations in Suzhou, China.
SEATTLE, Oct. 24, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate therapeutics for cancer, announced that management will be participating in one-on-one meetings with investors at the Wells Fargo 2023 Virtual Private Biotech Symposium on Wednesday, November 1, 2023 and at the Piper Sandler 35th Annual Healthcare Conference from November 28 – November 30, 2023.
"We look forward to participating in these conferences to discuss our emerging clinical data from SITC and company growth plans with investors" said Baiteng Zhao, PhD, CEO of ProfoundBio. "This is an exciting time for ProfoundBio as we explore the potential for our innovative ADC technology platform in the clinical setting."
About ProfoundBio
ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple antibody-drug conjugate (ADC) drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages. The company's clinical stage programs are rinatabart sesutecan (Rina-S; PRO1184), an ADC targeting folate receptor alpha, PRO1160, an ADC targeting CD70, and PRO1107, an ADC targeting PTK7. ProfoundBio is headquartered in Seattle, WA, USA.
